These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 23956442)

  • 21. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
    Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
    Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib.
    Fujita T; Iwamura M; Ishii D; Tabata K; Matsumoto K; Yoshida K; Baba S
    Int J Urol; 2012 Oct; 19(10):908-13. PubMed ID: 22671963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sorafenib induced eruptive melanocytic lesions.
    Uhlenhake EE; Watson AC; Aronson P
    Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
    Motzer RJ; Nosov D; Eisen T; Bondarenko I; Lesovoy V; Lipatov O; Tomczak P; Lyulko O; Alyasova A; Harza M; Kogan M; Alekseev BY; Sternberg CN; Szczylik C; Cella D; Ivanescu C; Krivoshik A; Strahs A; Esteves B; Berkenblit A; Hutson TE
    J Clin Oncol; 2013 Oct; 31(30):3791-9. PubMed ID: 24019545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study.
    Gore ME; Jones RJ; Ravaud A; Kuczyk M; Demkow T; Bearz A; Shapiro J; Strauss UP; Porta C
    BJU Int; 2017 Jun; 119(6):846-853. PubMed ID: 27981711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
    Fukudo M; Ito T; Mizuno T; Shinsako K; Hatano E; Uemoto S; Kamba T; Yamasaki T; Ogawa O; Seno H; Chiba T; Matsubara K
    Clin Pharmacokinet; 2014 Feb; 53(2):185-96. PubMed ID: 24135988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolonging survival in metastatic renal cell carcinoma patients treated with targeted anticancer agents: a single-center experience of treatment strategy modifications.
    Ninomiya N; Tamada S; Kato M; Yamasaki T; Iguchi T; Nakatani T
    Can J Urol; 2015 Jun; 22(3):7798-804. PubMed ID: 26068628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
    Naito S; Sakai H; Hashine K; Tomita Y; Shinohara N; Fujisawa M; Eto M; Ozono S; Akaza H
    Ann Oncol; 2015 Sep; 26(9):1871-1876. PubMed ID: 26117830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China.
    Zheng Y; Wang F; Wu G; Zhang L; Wang Y; Wang Z; Chen P; Wang Q; Lu J; Wang Y; Li P; Wang J; Lu X; Yuan J
    Medicine (Baltimore); 2015 Dec; 94(49):e2222. PubMed ID: 26656362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
    Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
    BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial.
    Hutson TE; Al-Shukri S; Stus VP; Lipatov ON; Shparyk Y; Bair AH; Rosbrook B; Andrews GI; Vogelzang NJ
    Clin Genitourin Cancer; 2017 Feb; 15(1):72-76. PubMed ID: 27498023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma.
    Ikeda M; Fujita T; Mii S; Tanabe K; Tabata K; Matsumoto K; Satoh T; Iwamura M
    Jpn J Clin Oncol; 2012 Sep; 42(9):820-4. PubMed ID: 22782962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
    Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).
    Zhou Q; Zhou CC; Chen GY; Cheng Y; Huang C; Zhang L; Xu CR; Li AW; Yan HH; Su J; Zhang XC; Yang JJ; Wu YL
    Lung Cancer; 2014 Mar; 83(3):369-73. PubMed ID: 24440279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience.
    Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu GK; Lokanatha D; Jacob LA; Suresh Babu MC; Lokesh KN; Rajeev LK
    Indian J Cancer; 2017; 54(4):626-630. PubMed ID: 30082547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.
    Procopio G; Derosa L; Gernone A; Morelli F; Sava T; Zustovich F; De Giorgi U; Ferrari V; Sabbatini R; Gasparro D; Felici A; Burattini L; Calvani N; Lo Re G; Banna G; Pia Brizzi M; Rizzo M; Ciuffreda L; Iacovelli R; Ferraù F; Taibi E; Bracarda S; Porta C; Galligioni E; Contu A
    Future Oncol; 2014 Aug; 10(10):1741-50. PubMed ID: 24641206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.